Viridian Therapeutics, Inc. | LinkedIn (original) (raw)

``

Biotechnology Research

Waltham, Massachusetts 10,525 followers

Framing the future of autoimmune diseases

About us

Viridian is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas. Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. Viridian’s goal is to advance VRDN-001 as a potential best-in-class intravenous therapy followed by VRDN-003 as a potential first- and best-in-class subcutaneous therapy for the treatment of TED. In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.

Industry

Biotechnology Research

Company size

51-200 employees

Headquarters

Waltham, Massachusetts

Type

Public Company

Founded

2007

Locations

Employees at Viridian Therapeutics, Inc.

Updates

Join now to see what you are missing

Join now

Similar pages

Browse jobs

Funding